Clinical Trials Logo

Clinical Trial Summary

Although the majority of tibial fractures heal normally, some fractures may not heal within the usual time frame and is known as delayed bone healing within 4 to 6 months and absence of bone healing within 9 to 12 months in the most severe case of. Several factors can increase the risks of delayed healing complications like, for example, smoking, violent shocks (for example, due to a road accident) or even the type of fracture (an open fracture). The location of the fracture is also an important factor: among the bones of the arms and legs, the tibia is known for being the most at risk for complications. At tibial fracture with several risk factors could lead to delayed complications and interfere with patient daily life and reduce the quality of life. The study drug, ALLOB®, is constituted of bone cells produced from the bone marrow of healthy adult donors. Preclinical studies have shown that ALLOB® cells are capable of forming bone and repairing fractures. When directly injected into a fracture, ALLOB® should therefore promote the healing of the fracture by re-establishing a healthy environment and stimulating bone production. To date, there is no treatment for fractures considered at risk of delayed complications. The current practice on diagnosis of complications is to wait at least 6-12 months before considering alternative interventions to promote fracture healing. The injection of ALLOB® quickly after the fracture should stimulate bone healing, reduce healing time, reduce complications, and improve the quality of life for the patient. ALLOB® has already shown preliminary evidence of effectiveness in the treatment of delayed bone healing fractures (ALLOB-DU1 clinical trial), including tibial fractures (8 patients). With this study, the Sponsor will evaluate whether ALLOB® promotes the healing of tibial fractures compared with placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04432389
Study type Interventional
Source Bone Therapeutics S.A
Contact Olivier Godeaux, MD
Phone +32 (0)71 121000
Email clinicaltrials@bonetherapeutics.com
Status Recruiting
Phase Phase 2
Start date January 8, 2021
Completion date March 31, 2024

See also
  Status Clinical Trial Phase
Terminated NCT01927575 - Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury N/A
Completed NCT01017094 - Pin Site Infection Prevention for Open Tibial Fracture Phase 3
Completed NCT00038129 - SPRINT - Randomized Trial of Tibial Fracture Fixation N/A
Recruiting NCT01795287 - Safety of Spinal Anesthesia in Patients With Tibial Shaft Fracture N/A
Terminated NCT01300520 - The Development of a Surgical Localizing Aid Medical Device N/A
Active, not recruiting NCT05012449 - Transitional Ankle Fracture Management Using a New Joystick Technique N/A
Suspended NCT00365573 - Doppler Ultrasonography Evaluation of Tibial Fracture Site Vascularity Phase 2
Completed NCT02820363 - Study Evaluating CERAMENTâ„¢|G in Open Diaphyseal Tibial Fractures N/A
Completed NCT00264511 - Hyperbaric Oxygen in Lower Leg Trauma Phase 2/Phase 3
Completed NCT04028908 - Remodelling After Trampoline Fracture in Children
Completed NCT02140528 - Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures Phase 2
Active, not recruiting NCT03598530 - Fracture-Related Outcome Study for Operatively Treated Tibia Shaft Fractures
Not yet recruiting NCT01955577 - Vitamin D Supplement for Patients With Tibial Fracture Phase 1
Completed NCT00250302 - Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures Phase 1/Phase 2
Unknown status NCT02035917 - Comparison of Tibial Plateau Fractures Outcomes Treated With Non-locking and Locking Plate N/A